Regeneron Pharmaceuticals Inc (REGN)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 15,410
- Market Cap
- $72.9B
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
SentiSense also tracks daily options readings for Regeneron Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Regeneron Pharmaceuticals Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.